FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Potiga (ezogabine) Tablets
Status: Discontinuation
»Therapeutic Categories: Neurology

Expand all

GlaxoSmithKline (New 07/03/2017)

Company Contact Information:
908-293-5330

Presentation Posting Date Related Information
Potiga (ezogabine) Tablets 50 mg (NDC 0173-0810-59) 07/03/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy.
Potiga (ezogabine) Tablets 200 mg (NDC 0173-0812-59) 07/03/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy.
Potiga (ezogabine) Tablets 300 mg (NDC 0173-0813-59) 07/03/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy.
Potiga (ezogabine) Tablets 400 mg (NDC 0173-0814-59) 07/03/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English